Observations showing that activation of FXR directly leads to decrease in liver lipogenesis and amelioration of insulin sensitivity served as the rationale for the development of FXR agonists (e.g., obeticholic acid) as potential therapeutic agents for NAFLD (34, 35). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.